Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma

29 Sept 2010

Abstract excerpt

BACKGROUND: The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known. METHODS: We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20879880
DOI: 10.1056/nejmoa1001527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome after Reduced Chemotherapy for Intermediate-Risk NeuroblastomaPMID 20879880Read ↗

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531Semantic proximity Read ↗

Significance of <i>MYCN</i> Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group DatabaseSemantic proximity Read ↗

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children’s Oncology Group Study ANBL0531Semantic proximity Read ↗

Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastomaSemantic proximity Read ↗

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) ReportSemantic proximity Read ↗

Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab betaSemantic proximity Read ↗

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastomaSemantic proximity Read ↗

Neuroblastoma in Infants: Long Term Survival from INES Protocols - A SIOPEN StudySemantic proximity Read ↗

Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN StudySemantic proximity Read ↗

Clinical Significance of <i>MYCN</i> Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology GroupSemantic proximity Read ↗

Allelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with NeuroblastomaSemantic proximity Read ↗

Hyperdiploidy Plus Nonamplified <i>MYCN</i> Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.